Editorial Videos

Ryan Last, senior associate at Troutman Pepper Locke explains how existing regulations and potential foreign countermeasures have a significant impact on reshoring efforts.

Troutman Pepper Locke senior associate Ryan Last explains how thin margins on certain product will impact the effectiveness of tariffs.

Ryan Last, senior associate at Troutman Pepper Locke, details the key steps that pharma companies must make before the July 31st deadline hits.

Aprecia’s president and COO discusses the benefits of using 3D printing technology to quickly produce high quality drug tablet in a variety of dosages.

Kyle Smith, president and COO of Aprecia, explains how the EQUIP-A-Pharma program is promoting the reshoring of pharma and biotech manufacturing.

Aprecia’s president and COO Kyle Smith explains the challenges domestic manufacturers face when sourcing certain API and materials.

Kyle Smith, president and COO of Aprecia, discusses how additive manufacturing allows for the rapid development and manufacturing of a variety of dosage forms.

As GLP-1 therapies reshape obesity care, Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, argues that lasting progress depends on targeting metabolic health, not just the number on the scale.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains what sets his company's obesity strategy apart in an increasingly crowded field.

Silvia Taylor of Novavax explains how major biotechs like Eli Lilly and Sanofi are developing vaccine strategies for the coming years.

Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across the industry.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, notes how scale is a starting point, not a finish line, and until clinicians measure what's happening inside the body, obesity treatment will keep falling short of its promise.

Silvia Taylor of Novavax discusses the role that regulatory agencies play in vaccine usage, who can receive vaccines, how they’re administered, and under what conditions.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, argues the field must evolve beyond the scale, measuring success not just in pounds lost, but in visceral fat reduction, liver health, and preserved muscle mass.

Polaryx’ chief medical officer Lisa Bollinger explains the struggles finding ways to reduce patient costs for gene therapies for rare diseases.

Lisa Bollinger, chief medical officer at Polaryx, explains how treatments for lysosomal disorders struggle due to the fact that these diseases each have a unique mutation.

Silvia Taylor of Novavax discusses how new vaccine technologies are reducing side effects, lowering costs, and enhancing immune response.

Polaryx’s chief medical officer Lisa Bollinger explains how basket-trials are uniquely beneficial to rare disease therapy development.

Lisa Bollinger, chief medical officer at Polaryx, discusses signs that regulatory agencies are taking the issues related to rare disease therapy development seriously.

With recent leadership shakeups, many are wondering how FDA will change its approach to regulating DTC pharma advertisements.

Former chief counsel for FDA Dan Troy explains why there is no firm timeline for regulatory reform or update at FDA for DTC pharma advertisements.

Dan Troy, former FDA chief counsel, explains limits on what regulations FDA can put on DTC advertisements.

Former FDA chief counsel Dan Troy discusses the motivation behind potential DTC pharma ad bans.

Harpreet Singh, MD, notes that FDA’s internal AI system could improve efficiency in drug review by helping reviewers aggregate and synthesize complex data.

Harpreet Singh, MD, touches on how the Commissioner’s National Priority Voucher program is accelerating regulatory review timelines without fundamentally changing how pivotal trials are designed.

Kevin Dondarskit of Deloitte Consulting discusses the risks that drug makers face if they decide to put too much focus on an area where they may lack expertise, such as the emerging GLP-1 market.

Kevin Dondarskit of Deloitte Consulting discusses how pharma companies are focusing on high-value assets that serve large patient populations.

Harpreet Singh, MD, notes that the FDA’s broader shift toward accepting single pivotal trials reflects an evolution in regulatory thinking, while noting the agency still weighs disease severity, unmet need, trial design, and long-term safety